SAN FRANCISCO, California — Linkage Biosciences announced the launch of a wholly owned European subsidiary located in Geneva, Switzerland. The launch reflects the company’s rapid growth and increasing global demand for LinkS?q™, the world’s fastest and simplest method of molecular tissue typing, allowing the identification of all classical Human Leukocyte Antigen (HLA) genes in a single test.

“Linkage is seeing great success with adoption of LinkS?q by numerous laboratories throughout Europe,” said Linkage Biosciences’ CEO Zachary Antovich. “Our new Swiss operations will extend our global reach and provide superior support and service to customers across the region.”

Linkage’s new office is set within Fongit, one of Geneva’s leading technology clusters, supporting innovative companies in Medtech, IT, and Cleantech industries. Mr. Pierre Maudet, former Mayor of Geneva and now State Councilor in charge of the Department of Security and Economy for the State of Geneva said, “We are delighted Linkage Biosciences has chosen to locate in Switzerland and specifically the Geneva and BioAlps life sciences community. Geneva offers a central location, strong life sciences network, and many benefits to support the growth and adoption of Linkage’s exciting technology.”

The new subsidiary gives Linkage a dedicated presence in the heart of Europe and will support its on-going commercialization efforts as well as provide a foundation for future development.